603387 基蛋生物
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入321,583-16.32%1,369,1621,821,8611,401,7011,123,336
减:营业总成本220,695-16.32%1,081,7811,253,787982,672803,995
    其中:营业成本91,733-15.90%446,065636,392482,461415,297
               财务费用(7,500)288.76%(50,365)(31,709)(3,157)(605)
               资产减值损失(818)-93.18%(19,246)(35,164)(2,955)880
公允价值变动收益1,343-81.03%10,24518,459(4,295)24,407
投资收益(1,281)-112.08%15,48516,05727,85618,133
    其中:对联营企业和合营企业的投资收益(523)-106.31%(2,614)7212,043(1,580)
营业利润100,432-27.52%306,588563,256452,788377,997
利润总额100,055-27.24%304,942559,979451,633374,040
减:所得税费用12,618-4.01%20,86156,03439,62243,727
净利润87,437-29.70%284,080503,945412,011330,313
减:非控股权益1,423-49.97%4,3095,03513,02125,580
股东净利润86,013-29.22%279,772498,910398,990304,733

市场价值指针
每股收益 (元) *0.170-29.17%0.5500.9800.7900.840
每股派息 (元) *----0.2000.3000.3400.360
每股净资产 (元) *5.2181.65%5.0464.8955.7907.060
审计意见 #----标准无保留意见标准无保留意见--
回页顶
备注: *未调整数据
#只提供简体内容